A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your partner of choice for viral vector development scale-up, analytics and GMP processing.
Leverage our expertise and state-of-the-art bioprocessing facilities and purpose built laboratories to help to achieve commercialisation of your viral vector-based products.
Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations.
Additionally, Oxford Biomedica has a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Discover how we drive credible science to help you realise incredible results - visit www.oxb.com or email email@example.com.